Physician profile
Chad A Link
NPI 1750504585
$315,431.36
in general payments reported to CMS, 2019-2025
40 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $53K · 2021: $44K · 2022: $40K · 2023: $54K · 2024: $39K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Food and Beverage: $5,717 · Consulting Fee: $4,680 · Travel and Lodging: $4,241 · Education: $88.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101,965.00 |
| Food and Beverage | $5,716.67 |
| Consulting Fee | $4,680.00 |
| Travel and Lodging | $4,240.80 |
| Education | $88.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $111,852.73 | 2019-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals Lp | $51,703.97 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Pfizer INC. | $45,484.56 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36,847.35 | 2019-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $20,115.54 | 2024 | Arcalyst |
| Lilly USA, LLC | $15,557.50 | 2020-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $13,049.14 | 2019-2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $9,946.40 | 2019-2022 | |
| Johnson & Johnson Health Care Systems INC. | $4,564.98 | 2023-2025 | Opsumit, Uptravi, Veletri |
| Boston Scientific Corporation | $888.26 | 2019-2025 | Watchman Flx, Watchman Access System, Eluvia |
| Novartis Pharmaceuticals Corporation | $761.44 | 2019-2025 | |
| Celgene Corporation | $600.00 | 2022 | |
| Amgen INC. | $487.86 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $392.74 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $385.87 | 2019-2025 |
Show all 36 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.